Table 4.

Hematologic and cytogenetic responses in bosutinib trials.

Stage of diseaseCHR, % (n)MCyR, % (n)CCyR, % (n)
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; n, number evaluable; TKi, tyrosine kinase inhibitor. 
Chronic phase24  
    Exposed to imatinib only 89 (38) 41 (56) 36 (56) 
    Exposed to imatinib and other TKIs 77 (13) 20 (10) — — 
Accelerated phase25  
    Exposed to imatinib only 50 (8) 44 (9) 22 (9) 
    Exposed to imatinib and other TKIs 11 (9) 0 (6) 0 (6) 
Blast crisis25  
    Exposed to imatinib only 15 (13) 18 (11) 9 (11) 
    Exposed to imatinib and other TKIs 7 (14) 20 (10) 20 (10) 
Stage of diseaseCHR, % (n)MCyR, % (n)CCyR, % (n)
Abbreviations: CHR, complete hematologic response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; n, number evaluable; TKi, tyrosine kinase inhibitor. 
Chronic phase24  
    Exposed to imatinib only 89 (38) 41 (56) 36 (56) 
    Exposed to imatinib and other TKIs 77 (13) 20 (10) — — 
Accelerated phase25  
    Exposed to imatinib only 50 (8) 44 (9) 22 (9) 
    Exposed to imatinib and other TKIs 11 (9) 0 (6) 0 (6) 
Blast crisis25  
    Exposed to imatinib only 15 (13) 18 (11) 9 (11) 
    Exposed to imatinib and other TKIs 7 (14) 20 (10) 20 (10)